Pharmazz, Inc., a late-stage biopharmaceutical company, showcased its lead drug, Sovateltide, at the International Pharmacology Conference & 54th Annual Conference of Indian Pharmacological Society (IPC-IPSCON 2024) held on November 29 in New Delhi, India. Dr. Anil Gulati, Chairman and CEO of Pharmazz, delivered an oral presentation titled "Successful development of a pharmacological concept to treat cerebral stroke patients," which highlighted key Phase 3 trial results.
Sovateltide, an endothelin-B agonist, is the first-in-class drug for acute cerebral ischemic stroke. The double-blind, placebo-controlled, multicenter Phase 3 clinical trial conducted in India demonstrated statistically significant improvements in neurological outcomes. Participants treated with Sovateltide exhibited a higher proportion of modified Rankin Scale (mRS) scores of 0-2 at 90 days compared to the control group, indicating favorable outcomes.
Dr. Gulati emphasized the importance of these findings, stating that Sovateltide offers hope to millions by addressing the complex neurological challenges associated with cerebral ischemic stroke. The drug has already impacted over 50,000 patients in India since its launch in September 2023, following regulatory approval.
Pharmazz is preparing for a larger multinational Phase 3 trial, which marks a significant step in advancing treatment options for cerebral ischemic stroke globally. The company is dedicated to developing innovative therapies for critical care, with a pipeline that includes two approved drugs in India and two Phase 3-ready programs in the United States.